The influence of polymorphisms of the β2- adrenoceptor (AR) gene and the β2-AR upstream peptide (BUP) on bronchoprotective tolerance development in asthmatic patients

A. van Veen, E. A. Wierenga, F. R. Weller, H. M. Jansen, R. E. Jonkers (Amsterdam, The Netherlands)

Source: Annual Congress 2001 - Long-acting β2-agonists: clinical effects
Session: Long-acting β2-agonists: clinical effects
Session type: Oral Presentation
Number: 3475
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. van Veen, E. A. Wierenga, F. R. Weller, H. M. Jansen, R. E. Jonkers (Amsterdam, The Netherlands). The influence of polymorphisms of the β2- adrenoceptor (AR) gene and the β2-AR upstream peptide (BUP) on bronchoprotective tolerance development in asthmatic patients. Eur Respir J 2001; 16: Suppl. 31, 3475

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Lack of effect of promoter, coding and 3‘ polymorphisms of the β2-adrenergic receptor (ADRB2) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008

Arg16Gly polymorphism of the β2-adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthma
Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment
Year: 2008

The presence of the arginine-16 β2-adrenoceptor polymorphism (β2-ARP) predisposes to bronchoprotective subsensitivity with long-acting β2-agonists
Source: Eur Respir J 2002; 20: Suppl. 38, 307s
Year: 2002

Effects of β2 agonists on mucociliary clearance (MCC) in patients with asthma - association to polymorphisms of the β2-adrenoceptor
Source: Eur Respir J 2003; 22: Suppl. 45, 478s
Year: 2003

Glucocorticosteroid receptor (GCR) gene isoforms expression in bronchial asthma (BA) patients
Source: Annual Congress 2011 - Asthma: a heterogeneous disease
Year: 2011


Differences in bronchoprotective subsensitivity between formoterol (FM) and salmeterol (SM) are associated with β2-adrenoceptor polymorphism
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002

ADRB2 Gly16Arg polymorphism, asthma control and lung function decline
Source: Eur Respir J 2011; 38: 1029-1035
Year: 2011



β2 adrenoreceptor polymorphisms, asthma control and lung function decline in the ecrhs
Source: Annual Congress 2009 - Asthma genetics: from genome wide to single nucleotide polymorphisms
Year: 2009

ADRB2R gene polymorphism (pol.) associated with the severity of cystic fibrosis(CF) and the effectiveness of the use of inhaled bronchodilator
Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies
Year: 2010

The associations of polymorphism C3435T multidrug resistance gene (MDR1) and regimen of inhaled glucocorticosteroid therapy in bronchial asthma (BA) patients
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

The gln27 beta adrenoceptor polymorphism is associated with bronchodilator reversibility in subjects with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 96s
Year: 2002

Effects of Arg16Gly polymorphism in ADRB2 gene on responses to salmeterol or montelukast added to inhaled corticosteroids in Japanese asthmatic subjects
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

The influence of antileukotriene therapy with montelukast (M) on thromboxane B2/leukotriene E4 (TXB2/LTE4) ratio in the urine of asthmatic subjects and other inflammatory markers
Source: Eur Respir J 2003; 22: Suppl. 45, 102s
Year: 2003

A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA)
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015


The pharmacogenetic effect of ADRB2 polymorphisms on therapeutic response in COPD
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012


Salmeterol response is not affected by beta2-adrenergic receptor genotype in patients with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 505s
Year: 2005

Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016


PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial
Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Year: 2020




Evidence for a non-β2-adrenoceptor (β2AR) binding site in human lung tissue for the long acting β2-agonist (LABA) vilanterol
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012

Analysis of glucocorticoid receptor gene polymorphisms in asthmatic children
Source: Eur Respir J 2007; 30: Suppl. 51, 710s
Year: 2007